164 related articles for article (PubMed ID: 38541221)
21. Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab.
Masamoto Y; Taoka K; Maki H; Kurokawa M
Ann Hematol; 2022 Dec; 101(12):2795-2797. PubMed ID: 36192661
[No Abstract] [Full Text] [Related]
22. Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction.
Hara T; Suzuki R; Ohno A; Yamakawa K; Yamagishi Y; Sugiyama Y; Sobajima T; Yamada R; Matsumoto R; Ikeda Y; Murayama M; Tsurumi H
Int J Hematol; 2020 Apr; 111(4):585-590. PubMed ID: 31848991
[TBL] [Abstract][Full Text] [Related]
23. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
[TBL] [Abstract][Full Text] [Related]
24. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
Haukaas FS; Ohna A; Krivasi T
Appl Health Econ Health Policy; 2018 Aug; 16(4):569-577. PubMed ID: 29923173
[TBL] [Abstract][Full Text] [Related]
27. The role of obinutuzumab in the management of follicular lymphoma.
O'Nions J; Townsend W
Future Oncol; 2019 Nov; 15(31):3565-3578. PubMed ID: 31538821
[TBL] [Abstract][Full Text] [Related]
28. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.
Davies A; Kater AP; Sharman JP; Stilgenbauer S; Vitolo U; Klein C; Parreira J; Salles G
Future Oncol; 2022 Aug; 18(26):2943-2966. PubMed ID: 35856239
[TBL] [Abstract][Full Text] [Related]
29. Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma.
Masamoto Y; Shimura A; Honda A; Taoka K; Maki H; Kurokawa M
Ann Hematol; 2023 Jan; 102(1):243-244. PubMed ID: 36369496
[No Abstract] [Full Text] [Related]
30. Management of patients with follicular lymphoma treated first line with obinutuzumab.
Opat S; Dickinson M; Cheah CY; Tam C; Boulos J; Thorburn AN; Trotman J
Asia Pac J Clin Oncol; 2019 May; 15 Suppl 3():3-11. PubMed ID: 31058467
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.
Qin Y; Song Y; Shen Z; Du X; Ji W; Hsu W; Zhu J; Shi Y
Cancer Commun (Lond); 2018 May; 38(1):31. PubMed ID: 29843792
[TBL] [Abstract][Full Text] [Related]
32. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
33. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.
Klanova M; Oestergaard MZ; Trněný M; Hiddemann W; Marcus R; Sehn LH; Vitolo U; Bazeos A; Goede V; Zeuner H; Knapp A; Sahin D; Spielewoy N; Bolen CR; Cardona A; Klein C; Venstrom JM; Nielsen T; Fingerle-Rowson G
Clin Cancer Res; 2019 Aug; 25(15):4634-4643. PubMed ID: 31053601
[TBL] [Abstract][Full Text] [Related]
35. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
Morschhauser F; Salles G; Le Gouill S; Tilly H; Thieblemont C; Bouabdallah K; Fabiani B; Ménard C; Tarte K; Cartron G; Houot R
Blood; 2018 Oct; 132(14):1486-1494. PubMed ID: 30068505
[TBL] [Abstract][Full Text] [Related]
36. Occurrence of Infusion-Related Reactions due to Obinutuzumab Therapy for Follicular Lymphoma.
Azuma K; Matsuo K; Nemoto M; Uekusa S; Yokoyama M; Terui Y; Hama T; Yoshio T
Gan To Kagaku Ryoho; 2021 Nov; 48(11):1369-1373. PubMed ID: 34795129
[TBL] [Abstract][Full Text] [Related]
37. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.
Fujiwara Y; Urata T; Niiya D; Yano T; Nawa Y; Yoshida I; Imai T; Sunami K; Fujii S; Ennishi D; Maeda Y; Hiramatsu Y
Int J Hematol; 2022 Jun; 115(6):811-815. PubMed ID: 35583725
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
39. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.
Rogers LM; Mott SL; Smith BJ; Link BK; Sahin D; Weiner GJ
Clin Cancer Res; 2017 Feb; 23(4):954-961. PubMed ID: 27528699
[No Abstract] [Full Text] [Related]
40. [Lethal enterovirus myocarditis associated with rituximab and chemotherapy for follicular lymphoma].
Alonso JJ; Cánovas A; Rubio G
Med Clin (Barc); 2013 Nov; 141(10):459-60. PubMed ID: 23622890
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
